{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-23-000114","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2023-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.158310+00:00","generated_at":"2026-06-10T08:46:27.236959+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Immunovant announces positive initial Phase 1 data for IMVT-1402 with IgG reductions and no albumin or LDL-C changes","bullets":["Mean total IgG reduction of 63% after four weekly 300 mg SC doses of IMVT-1402 in Phase 1 MAD cohort.","No decrease in serum albumin below baseline or increase in LDL-C above baseline observed after 4 weeks.","Subcutaneous doses of IMVT-1402 achieved peak IgG reductions similar to those previously seen with batoclimab.","All adverse events were mild or moderate; dosing for 600 mg cohort has recently begun.","Immunovant hosted a conference call and webcast on September 26, 2023 to discuss the data."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-23-000114","json":"https://secwatch.observer/filing/0001764013-23-000114.json","markdown":"https://secwatch.observer/filing/0001764013-23-000114.md","text":"https://secwatch.observer/filing/0001764013-23-000114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000114/0001764013-23-000114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000114/imvt-20230926.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:46:27.236959+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}